Expression and clinical significance of USP20 in oral squamous cell carcinoma

doi:10.19439/j.sjos.2024.05.004

Abstract

Abstract: PURPOSE: To investigate the expression of ubiquitin specific protease 20 (USP20) in oral squamous cell carcinoma (OSCC) and its correlation with clinicopathological parameters. METHODS: OSCC samples and paired paracancerous samples were screened from the TCGA database for differential expression analysis and paired differential analysis. Immunohistochemical staining was used to detect the expression level of USP20 in OSCC tissue, paracancerous tissues and normal tissues. The correlation between USP20 expression level and clinicopathological parameters of tissue microarray was analyzed. GraphPad Prism 9.5.0 software was used for statistical analysis of the data. RESULTS: TCGA data showed that the expression of USP20 in OSCC was significantly higher than that in paracancerous tissue(P<0.001). Immunohistochemical staining score showed that the expression of USP20 in OSCC was significantly higher than that in paracancerous tissues and normal tissues(P<0.01). The analysis of clinicopathological indicators of tissue microarray showed that the staining scores of USP20 were significantly different in tumor differentiation (P<0.05) and primary tumor size (P<0.01). Kaplan-Meier survival analysis indicated no significant difference in overall survival time and 5-year survival rate between high expression group and low expression group (P>0.05). CONCLUSIONS: USP20 is highly expressed in OSCC compared with paracancerous tissues and normal oral tissues. The expression of USP20 is associated with differentiation and the size of primary tumor in OSCC,and can accelerate its growth.

Key words: Oral squamous cell carcinoma, USP20, Bioinformatics, Immunohistochemistry, Clinicopathological indicators

CLC Number:

R739.8

ZHAI Xiao-qi, LIU Bo, SHENG Cheng-yi, HOU Rui, TANG Chao-nan, GUAN Jian. Expression and clinical significance of USP20 in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2024, 33(5): 466-470.

References

[1] Chen R, Zhu S, Zhao R, et al.Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma[J]. Front Pharmacol, 2024, 15: 1402514.
[2] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] Chamoli A, Gosavi AS, Shirwadkar UP, et al.Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics[J]. Oral Oncol, 2021, 121: 105451.
[4] Rodrigues AAN, Lopes-Santos L, Lacerda PA, et al.Heparanase 1 upregulation promotes tumor progression and is a predictor of low survival for oral cancer[J]. Front Cell Dev Biol, 2022, 10: 742213.
[5] Hu S, Chen X, Zhu M, et al.Expression, purification and characterization of the second DUSP domain of deubiquitinase USP20/VDU2[J]. Protein Expr Purif, 2021,181: 105836.
[6] Qin B, Zhou L, Wang F, et al.Ubiquitin-specific protease 20 in human disease: Emerging role and therapeutic implications[J].Biochem Pharmacol, 2022, 206: 115352.
[7] Li Q, Ye C, Tian T, et al.The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeutics[J]. Cell Death Dis, 2022, 13(5): 434.
[8] Jin R, Luo Z, Jun-Li, et al.USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis, immune infiltration and chemotherapy resistance[J]. Front Oncol, 2023,13: 1023292.
[9] Li Z, Wang D, Messing EM, et al.VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha[J]. EMBO Rep, 2005, 6: 373-378.
[10] Ha J, Kim M, Seo D, et al.The deubiquitinating enzyme USP20 regulates the TNFα-induced NF-κB signaling pathway through stabilization of p62[J]. Int J Mol Sci, 2020, 21(9): 3116-3119.
[11] Zhu M, Zhao H, Liao J, et al.HERC2/USP20 coordinates CHK1 activation by modulating CLASPIN stability[J]. Nucleic Acids Res, 2014, 42: 13074-13081.
[12] Wang C, Yang C, Ji J, et al.Deubiquitinating enzyme USP20 is a positive regulator of Claspin and suppresses the malignant characteristics of gastric cancer cells[J]. Int J Oncol, 2017, 50(4): 1136-1146.
[13] 申洪, 陆药丹. 免疫组织化学染色的定量方法研究[J]. 生物医学工程学杂志, 1993, 10(4): 281-284.
[14] Bera RN, Tandon S, Singh AK, et al.Management and outcome of locally advanced oral squamous cell carcinoma[J]. Natl J Maxillofac Surg, 2023, 14(2): 185-189.
[15] Li W, Shen M, Jiang YZ, et al.Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2[J]. Genes Dev, 2020, 34(19-20): 1310-1315.
[16] 周方方, 朱晓华, 荣欣欣, 等. 泛素特异蛋白酶20在乳腺癌组织中的表达及其临床意义[J]. 川北医学院学报, 2017, 32(5): 659-661,665.
[17] Guan Y, Jiang SR, Liu JG, et al.USP20 regulates the stability of EMT transcription factor SOX4 and influences colorectal cancer metastasis[J]. Pathol Res Pract, 2022, 233: 153879.